MedTrace Logo

Role of Pioglitazone in Preventing Diabetes

NCT00276497 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2009-04-06

No results posted yet for this study

Summary

A three year prospective, double blinded, placebo controlled, randomized clinical trial in impaired glucose tolerance (IGT) subjects to study the effect of pioglitazone in preventing the conversion to Diabetes.

Conditions

Interventions

DRUG

Pioglitazone

Sponsors & Collaborators

  • India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals

    collaborator OTHER

  • M.V. Hospital for Diabetes

    lead OTHER

Principal Investigators

  • Ambady Ramachandran, MD,PhD,DSc · India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes hospitals, 28, Marshall's Road, Egmore, Chennai-600 008. India

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-10-31
Completion
2008-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00276497 on ClinicalTrials.gov